Business news with perspective

Bonerge is betting that cellular recovery is the key to mitigating the high cost of night shift work. Its real-world trial could redefine human capital investment.

Beyond 5 million sales, Pokémon Pokopia's success on the Switch 2 reveals a potent strategy blending cozy gaming with a lucrative, long-term DLC model.

The 2026 International Congress of Basic Science isn't just a meeting. It's a declaration of China's ambition to lead and a debate on AI's true role.

The deal signals a major food tech trend: consolidation for all-in-one platforms versus specialization, as iFoodDS doubles down on traceability.

With fully funded facilities and a US Army pact, REalloys is building a non-Chinese magnet supply chain. But can its strategic wins outweigh a $37M loss?

Binah Capital Group swings from a loss to a profit in Q2, crediting its unique model for empowering independent advisors. Is this a fluke or a new industry benchmark?

Firm Capital reports falling profits but holds its dividend steady. With a high payout ratio and a surge in new lending, is this a sign of resilience or risk?

Agoda and Singapore's Tourism Board are ditching old marketing playbooks for a new AI-powered strategy to create hyper-personalized travel and a smarter economy.

Stardust Power is breaking ground on a key US lithium refinery, but thin cash reserves and a reliance on future funding raise critical questions.

Greenlane Renewables posts a profit while doubling R&D and forging a key partnership with Panasonic. Is this the model for sustainable innovation?

With a novel drug platform and new funding, Akari Therapeutics aims to redefine cancer therapy. But can its groundbreaking science outpace a ticking financial clock?

The Chinese robotics firm posted record revenue but a staggering $5.6M loss. Is this a strategic masterstroke or a reckless bet on a future that may never pay off?

Fortress Biotech's Q2 net loss masks a cash-rich strategy. A $117M cash surge and major pipeline wins reveal a model built for the long haul.

MDB Capital celebrates a string of successful IPOs but reports a staggering $16.1M loss, putting its unique 'public venture' model under intense scrutiny.

With $4.4M in new funding, Clarity Systems is deploying AI scanners to see inside returns, fighting fraud without penalizing honest shoppers.

Caribou Biosciences reports impressive clinical data for its allogeneic CAR-T therapies, but the path to broader patient access hinges on a critical hurdle: funding.

Don't let headline numbers fool you. True North's Q2 reveals a 7.1% NOI surge and 96% occupancy, a testament to its sharp portfolio management.

Plunging revenues and a staggering net loss push IM Cannabis to the edge, forcing a desperate and bizarre strategic pivot from medical marijuana to military drones.

With a cash runway to 2029 and a novel cancer drug nearing key data, NuCana signals quiet confidence in a high-stakes race to treat resistant melanoma.

Soluna Holdings reports a 145% revenue surge but a widening net loss, revealing a bold strategy to trade short-term profits for a vast green AI infrastructure.